Fast track — ArticlesRisk of cardiovascular events and rofecoxib: cumulative meta-analysis
Introduction
On Sept 30, 2004, a press release from Merck announced the withdrawal of rofecoxib (Vioxx) because of an increased cardiovascular risk in patients taking the drug for more than 18 months.1 The decision was based on the 3-year results of the unpublished Adenomatous Polyp Prevention on Vioxx (APPROVe) study, a placebo-controlled trial of rofecoxib for the prevention of recurrence of colorectal polyps in patients with a history of colorectal adenomas. By the time it was withdrawn, rofecoxib had been taken by an estimated 80 million people and sales had reached US$2·5 billion in 2003.2
Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclo-oxygenase 2 (COX2). The COX enzyme is crucial to the formation of prostaglandins and exists in two isoforms, a constitutive isoform (COX1) and an inducible isoform that is expressed at sites of inflammation (COX2). The idea that anti-inflammatory effects are mediated through inhibition of COX2, whereas adverse gastrointestinal effects are attributable to inhibition of COX1, whose prostaglandins protect the gastric mucosa, led to the development of selective COX2 inhibitors.3 Approved by the US Food and Drug Administration (FDA) in 1999, COX2 inhibitors soon dominated the prescription-drug market for NSAIDs.
The safety profile of rofecoxib has been questioned since the Vioxx Gastrointestinal Outcomes Research trial (VIGOR),4 which noted a five-fold higher incidence of myocardial infarction in the rofecoxib group compared with the naproxen group.5, 6 Naproxen inhibits the production of thromboxane and platelet aggregation, and the difference in cardiovascular risk was attributed to a cardioprotective effect of naproxen, rather than a cardiotoxic effect of rofecoxib.4 This interpretation was reiterated in a 2001 meta-analysis of randomised trials of rofecoxib7 and three case-control studies of naproxen and myocardial infarction published in 2002.8, 9, 10
We report the results of a cumulative meta-analysis to establish whether robust evidence on the adverse effects of rofecoxib was available before September, 2004.
Section snippets
Methods
Literature search and inclusion criteria
We aimed to identify all randomised clinical trials that compared rofecoxib with another NSAID or placebo. We searched the Cochrane Controlled Trials Register (issue 3, 2004), and MEDLINE, EMBASE, and CINAHL (from inception to September, 2004). We combined a search for articles relating to rofecoxib with the Cochrane search strategy for randomised trials. We examined citations of key papers in the Science Citation Index, searched conference proceedings,
Results
Figure 1 summarises the process of identifying eligible clinical trials. 18 randomised controlled trials met inclusion criteria.4, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 We also identified 126 reports of observational studies on naproxen and cardiovascular risk. We excluded 62 articles on the basis of their abstracts and obtained the full-text articles for the remaining 64 reports. 11 observational studies met inclusion criteria.8, 9, 10, 29, 30, 31, 32, 33, 34, 35, 36
Discussion
The voluntary withdrawal of rofecoxib by its manufacturer, Merck, on the basis of a fairly small trial that was designed for a different purpose raises several questions.37 In particular, we must establish whether the drug should have been withdrawn earlier. Our cumulative meta-analysis of randomised controlled trials indicates that an increased risk of myocardial infarction was evident from 2000 onwards. At the end of 2000, the effect was both substantial and unlikely to be a chance finding.
We
References (49)
- et al.
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
Gastroenterology
(1999) - et al.
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
Clin Ther
(1999) - et al.
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study
Lancet
(2002) - et al.
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Lancet
(2002) - et al.
The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin
J Am Coll Cardiol
(2004) Vioxx: an unequal partnership between safety and efficacy
Lancet
(2004)- et al.
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone)
Am J Cardiol
(2002) The information wars
Lancet
(1999)Merck announces voluntary worldwide withdrawal of VIOXX®
Failing the public health: rofecoxib, Merck, and the FDA
N Engl J Med
(2004)
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis
Proc Natl Acad Sci USA
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
N Engl J Med
Risk of cardiovascular events associated with selective COX-2 inhibitors
JAMA
Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain
Arch Intern Med
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
Circulation
Association between naproxen use and protection against acute myocardial infarction
Arch Intern Med
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction
Arch Intern Med
Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis
Arch Intern Med
Lessons from the withdrawal of rofecoxib: patients would be safer if drug companies disclosed adverse events before licensing
BMJ
Measuring inconsistency in meta-analyses
BMJ
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib
J Rheumatol
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
Arthritis Rheum
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo of the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial
Arthritis Rheum
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
Arch Intern Med
Cited by (821)
Prevalence of and factors associated with potentially redundant randomized controlled trials: a cross-sectional study
2024, Journal of Clinical EpidemiologyHeart-on-a-chip systems: disease modeling and drug screening applications
2024, Lab on a ChipEfficacy and safety of anti-interleukin-1 therapeutics in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials
2023, Journal of Orthopaedic Surgery and ResearchAlveolar Type 2 Epithelial Cell Organoids: Focus on Culture Methods
2023, BiomedicinesHealthcare utilisation and mortality in people with osteoarthritis in the UK:
2023, British Journal of General Practice